Robert Enrico Pacifici, Ph.D., is Chief Scientific Officer of CHDI Management, Inc. / CHDI Foundation, Inc., a nonprofit drug discovery organization that supports an international network of research laboratories pursuing novel therapies for Huntington’s disease. Dr. Pacifici is responsible for the implementation and execution of the Foundation’s translational research program. He also is an adjunct professor in the Department of Molecular Pharmacology and Toxicology at the University of Southern California. Dr. Pacifici was formerly the Site Director and Chief Scientific Officer for Eli Lilly's Research Triangle Park Laboratories. Prior to that he was Vice President of Discovery Technologies at Xencor, a biotechnology company specializing in developing protein therapeutics. For more than a decade he was a research director and laboratory head at Amgen, Inc., coordinating and directing research automation technologies, high throughput screening and other programs. Currently, Dr. Pacifici chairs the steering committee for the NINDS Spinal Muscular Atrophy Project.
Last Modified January 24, 2012